REPROCELL Announces the Commercial Launch of its StemEdit Hypoimmune hiPSC Lines Generated with Advanced Gene Editing Innovations

Beltsville, MD, October 29, 2025 – REPROCELL currently offers hypoimmune hiPSC lines with HLA I/II knockouts (B2M/CIITA homozygous double KO) that employ StemEdit gene-editing technology using an alternate to popular research grade caspases. Caspases are specialized enzymes that can be engineered to precisely modify genetic material during gene editing. This approach provides a robust and strategic alternative to patented caspases and helps to navigate intellectual property constraints while maintaining high precision and editing efficiency. 

StemEdit Human iPSC non-HLA class 1 (B2M Homo KO) #C5 (RCRP044E)
StemEdit Human iPSC non-HLA class 1/2 (B2M/CIITA Homo double KO) #E1 (RCRP043E)

REPROCELL is now proud to announce the upcoming launch of additional hypoimmune hiPSC lines designed for both research and future clinical applications.

Looking ahead, REPROCELL is developing the next generation of these lines using a revolutionary AI designed caspase system that offers high efficiency and reduced off-target effects to advance gene editing. Cell lines generated with this new technology will be launched in early 2026.

Novel caspase systems with simple licensing structures for gene-edited products remain at the forefront of our current and future offerings, ensuring reliable and widely accessible gene editing solutions.

“The efficiency of the REPROCELL optimized editing system for KO’s and KI’s is impressive and has become my go-to service for iPS cell line engineering for therapeutic indication. The availability of clinical grade hypoimmune hiPSC line banks will mark a significant step forward in regenerative medicine. I commend REPROCELL for its commitment to empower researchers and clinicians with advanced tools for groundbreaking therapeutic development.” - commented Dr. Mahendra Rao, internationally recognized stem cell expert and founder of NKURE therapeutics and MD Bio.

About REPROCELL:

REPROCELL provides services and reagents to support the entire drug discovery pathway. BioServe-brand, established in 1989, provides researchers with access to our biorepository, molecular services, human tissue samples and services to support a wide variety of research and development, as well as provide a starting point for stem cell research. Stemgent-brand stem cell products and services, along with REPROCELL brand differentiated cells and reagents, enable researchers to bring the power of stem cells to bear on human disease. Alvetex-brand 3D culture products provide a physiologically relevant environment for cells that mimic the in vitro situation. Biopta-brand human tissue assays provide pharmaceutical companies with physiologically relevant information on human tissue prior to clinical trials. REPROCELL, founded in 2002, is based in Yokohama, Japan and has laboratories in Beltsville, MD, USA, Glasgow, UK and Hyderabad, India to support global research efforts.